PDGFRA and gastrointestinal stromal tumor: Olaratumab, a monoclonal antibody targeting platelet-derived growth factor receptor (PDGFR)-alpha, extended the overall survival of metastatic GIST [38] as well as non-GIST sarcomas [39].